New drug duo aims to wipe out lingering breast cancer cells
NCT ID NCT07191717
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two drugs, imlunestrant and abemaciclib, in 42 people with ER+ breast cancer who have tiny amounts of cancer DNA still in their blood after initial treatment. The goal is to see if the combination can clear these leftover cancer cells. Participants will take the drugs for up to 12 cycles and have blood samples and scans to track results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imlunestrant and abemaciclib
- What this could lead to
- If successful, this could lead to a new treatment option that clears remaining cancer cells from the blood, potentially reducing the risk of breast cancer recurrence.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to all patients. The drugs may cause side effects like fatigue or low blood cell counts, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Could a common cholesterol drug boost breast cancer treatment?